Receptos to Deliver Scientific Presentations at Digestive Disease Week 2013 About the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
5/16/2013 10:11:06 AM
More...
|
Receptos Announces Pricing of Initial Public Offering of Common Stock
5/9/2013 10:06:30 AM
More...
|
San Diego's Receptos, Ambit Biosciences, Get Ready for IPO Debuts
5/7/2013 7:52:32 AM
More...
|
Biotech Receptos Files for a $86 Million IPO
4/5/2013 7:44:19 AM
More...
|
Receptos Licenses AbbVie (ABBV) Antibody for Co-Development
3/13/2013 10:00:05 AM
More...
|
Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration With Ono Pharmaceutical Company, Ltd.
3/7/2013 10:12:12 AM
More...
|
Receptos Release: Graham Cooper Appointed Chief Financial Officer of Receptos
2/14/2013 7:35:33 AM
More...
|
Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis
1/4/2013 9:37:25 AM
More...
|
Receptos Doses First Patient in Phase 2/3 Trial for RPC1063 in Multiple Sclerosis
10/22/2012 9:45:17 AM
More...
|
Receptos to Deliver Scientific Presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
10/9/2012 11:01:53 AM
More...
|
|